Introduction
============

COPD is characterized by a progressive deterioration of lung function with some mental and physical comorbidities such as depression, dystrophy, and heart failure.[@b1-copd-11-2625] COPD is one of the important public health problems because of the high prevalence, mortality, and economic burden. The World Health Organization estimated that \>3 million people worldwide died of COPD in 2012, equal to 6% of all deaths globally that year, and \>90% of COPD deaths occurred in low- and middle-income countries, including China.[@b2-copd-11-2625] In China, a nationwide survey showed that the prevalence of COPD among people over 40 years old was 8.2% (12.4% for men and 5.1% for women) in 2008.[@b3-copd-11-2625] Based on the results of the Global Burden of Diseases Study, COPD was the third leading cause of death in China in 2010.[@b4-copd-11-2625]

COPD is a disease associated with substantial economic burden worldwide.[@b5-copd-11-2625],[@b6-copd-11-2625] Previous studies conducted in China showed that COPD was also costly and imposed an enormous economic burden on both families and society in the country. The average of annual direct medical costs (DMCs) and direct nonmedical costs (DNMCs; including costs caused by nutrition, transportation, and caregivers) in 2006 were RMB 11744 Yuan (US\$ 1473) and 1570 Yuan (US\$ 197), respectively, for each COPD patient living in urban areas of China. The average work loss was 17 days for COPD patients and 14 days for their relatives in 2006.[@b7-copd-11-2625] Previous studies had indicated that hospitalization is a major driver of DMCs for COPD and such DMCs are significantly correlated with the comorbidity and severity of COPD.[@b8-copd-11-2625]--[@b11-copd-11-2625] However, there have been so far limited data on the costs due to COPD in China, including direct and indirect costs (ICs) and factors related to the costs. This cross-sectional study was designed and conducted to provide the information for urban communities of China.

Patients and methods
====================

Study population
----------------

This multi-center cross-sectional study was carried out in four megacities, ie, Beijing, Guangzhou, Shanghai, and Chengdu, of China in 2011. Fifteen community health centers or hospitals participated in recruiting subjects from local communities. A total of 721 COPD patients were invited and 94% of them were eligible based on the inclusion criteria (local residents who lived in the city for at least 2 years without any unstable comorbidities or any severe conditions needed to be treated as inpatients). COPD cases who did not meet the inclusion criteria were excluded.[@b12-copd-11-2625] A written informed consent was obtained from all subjects. They were free to withdraw from the study at any time with no negative consequences. The ethics approval for this study was issued by the Institutional Review Board of the Fudan University School of Public Health. Further details are available in a previous publication.[@b12-copd-11-2625]

Data collection
---------------

Health workers were recruited as data collectors from each study site after they were trained by academic investigators. A structured questionnaire was used to collect direct medical and nonmedical costs as well as ICs. Investigators interviewed subjects, reviewed medical charts, and obtained detailed information on medical care utilization, transportation/nutrition costs, and work loss of COPD patients and caregivers. Free lung function testing was provided to all subjects during the survey.

Cost definition and estimation
------------------------------

The total costs of COPD included direct costs (DMCs and DNMCs) and ICs. In this study, the annual DMCs were all medical expenditures incurred by outpatient clinical visit, emergency, and hospitalization due to COPD, namely the total expenditures for treating COPD, including copayments, diagnoses, treatments, diagnostic tests, prescription drugs, and medical supplies in the previous 12 months. The annual DNMCs were all nonmedical expenditures including costs for transportation and costs for living care and nutrition. ICs referred to the costs caused by lost productivity, including work loss of patients and relatives as their caregivers, for which the authors used average day wages in 2010 (Beijing: RMB 65168/250 Yuan \[US\$ 10090/250\]; Shanghai: 66115/250 Yuan \[US\$ 10236/250\]; Chengdu: 32567/250 Yuan \[US\$ 5042/250\]; and Guangzhou: 40432/250 Yuan \[US\$ 6260/250\]) to estimate the ICs.[@b13-copd-11-2625] The cost figures were expressed in RMB and equivalent US dollars based on the average exchange rate of the study year.

Statistical analysis
--------------------

All data were double input into a database in EpiData3.1 Chinese version. Statistical analysis was completed using SPSS22. For continuous outcomes, median and/or mean ± standard deviation were used to describe the data, and Kruskal--Wallis or Wilcoxon test was used to test the differences of costs among groups. For categorical outcomes, frequencies (percentages) were provided and chi-square test was used to test different distributions. The upper quartile of total costs for COPD was calculated, and costs not less than top 25th percentile were defined as being high economic burden. Logistic regression model was used to calculate the crude odds ratio, adjusted odds ratio (aOR), and 95% confidence intervals (CIs) for factors associated with high economic burden. *P*\<0.05 was used to define statistical significance.

Results
=======

Characteristics of COPD patients
--------------------------------

Of the 678 participants, about a quarter of them were from four cities (Beijing: 25.1%; Guangzhou: 25.8%; Shanghai: 24.8%; and Chengdu: 24.3%). A majority of them were male (72.9%) and \>60 years old (82.9%). Approximately three-fifths of them had received ≤9 years of education (61.6%) and had monthly household income per capita between RMB 1,000 Yuan (US\$ 154) and 2,999 Yuan (US\$ 464) (60.7%). One-fifth (19.4%) remained current smokers. Almost all the patients (95.6%) had at least one type of medical insurances. The median duration of COPD was 4.0 years. A majority of the COPD patients had at least one comorbid chronic disease (79%). According to the criteria of the Global Initiative for Chronic Obstructive Lung Disease, 20.6% of them were in mild stage, 47.3% of them were in moderate stage, 26.7% of them were in severe stage, and 9.0% of them were in very severe stage ([Table 1](#t1-copd-11-2625){ref-type="table"}).

Costs for COPD
--------------

Of the 678 subjects, 68.5% visited a department of outpatient at least once during the past 3 months and 40.9% had hospitalization during the past year prior to the survey. The median annual direct costs, ICs, and total costs per patient due to COPD were RMB 6,096 Yuan (US\$ 944), 0 Yuan (US\$ 0), and 6,405 Yuan (US\$ 992), respectively ([Table 2](#t2-copd-11-2625){ref-type="table"}). Direct costs accounted for 86% of the total costs, and hospitalization costs were a major driver of the direct costs, accounting for 65.9% ([Figure 1](#f1-copd-11-2625){ref-type="fig"}). During the past 12 months, 12.8% of the patients reported that either they or their relatives were off work with a total of 5,944 workdays or a median of 2.2 workdays per patient because of their COPD. Caregivers' work loss accounted for 60.7% ([Table 2](#t2-copd-11-2625){ref-type="table"}).

COPD economic burden in China
-----------------------------

The ratio of annual total costs for COPD versus annual average income was similar for Beijing (34.1%), Guangzhou (32.8%), and Chengdu (32.3%) and was much lower for Shanghai (19.2%). There were 568 million people aged ≥40 years in China in 2010, and it was estimated that 8.2% of them or 46.6 million people had COPD, of whom only 35.1% or 16.3 million COPD had been diagnosed.[@b3-copd-11-2625] For this population of diagnosed COPD, the DMCs, DNMCs, and ICs were estimated to be approximately RMB 195.70 billion Yuan (US\$ 30.30 billion), 8.78 billion Yuan (US\$ 1.36 billion), and 34.10 billion Yuan (US\$ 5.28 billion), respectively. There may be a big difference in COPD care costs between large cities and other areas of the country.

COPD costs associated with patients' characteristics
----------------------------------------------------

Costs for outpatient visit and hospitalization were significantly correlated with age, household income, severity of COPD, and comorbidity. The costs increased with the number of comorbidities (annual DMCs, DNMCs, ICs, and total costs) and severity (annual DMCs, DNMCs, and total costs). Costs per outpatient visit were higher and costs per hospitalization were lower for patients aged \>60 years. The annual DNMCs and ICs were higher in women than in men but the annual DMCs showed no sex difference. The annual DMCs and total costs were higher in patients aged \>60 years ([Table 3](#t3-copd-11-2625){ref-type="table"}).

Logistic regression model was further applied to explore possible influencing factors for high total costs due to COPD ([Table 4](#t4-copd-11-2625){ref-type="table"}). After adjustment for study site and other covariates, there was a significantly greater risk of high costs for older patients (\>60 years) than for young patients (aOR =2.36, *P*=0.015). The risk of high costs increased significantly with the severity of COPD and the number of exacerbations. The aOR for high costs was 4.68 (95% CI: 2.71--8.08) for COPD patients with an acute exacerbation versus those without an acute exacerbation.

Discussion
==========

COPD is a well-known disease of high economic burden worldwide. This study demonstrated that COPD posed a huge economic burden in China, including RMB 195.70 billion Yuan (US\$ 30.30 billion) of DMCs, 8.78 billion Yuan (US\$ 1.36 billion) of DNMCs, and 34.10 billion Yuan (US\$ 5.28 billion) of ICs in 2010. In China, the total health expenditure (THE) was RMB 1998.04 billion Yuan (US\$ 309.35 billion) in 2010, accounting for 4.98% of GDP, and the THE per capita was RMB 2315.5 Yuan (US\$ 358.50) and 666.3 Yuan (US\$ 103.16) in urban and rural areas, respectively.[@b14-copd-11-2625] Thus, the estimated DMCs of COPD accounted for 9.8% of THE. In this study, the annual direct expenditure and total costs per patient were equivalent to 26.1% and 29.7% of their personal income, respectively, which were lower than those reported in previous studies conducted in 2006 and 2008--2009,[@b7-copd-11-2625],[@b15-copd-11-2625] but the annual direct expenditure was much higher than that estimated in the US (only 12.1%, US\$ 6,030/49,800).[@b16-copd-11-2625] The annual DMCs were higher than those reported in 2006 in China,[@b7-copd-11-2625] which were likely due to larger aging population and more expensive health care costs. A lower proportion of direct costs to personal income could have resulted from the rapid socioeconomic development recently in China. ICs accounted for \~14% of total costs, which was lower than that reported in the US (27%--61%).[@b17-copd-11-2625] One study noted that there was an increase in ICs on COPD in the past several years.[@b18-copd-11-2625] In this study, hospitalization costs accounted for 56.7% of the total costs, which were consistent with some prior studies.[@b7-copd-11-2625],[@b19-copd-11-2625]--[@b21-copd-11-2625] However, one study conducted in rural areas of China found that the direct costs were mainly driven by the costs of outpatient services (42.3%), followed by hospitalization costs (32.5%).[@b15-copd-11-2625] The difference between urban and rural areas may be due to health care disparities and different distributions of severity.

This study also revealed that age, disease severity, and acute exacerbations were the independent factors for high economic burden in COPD patients. In urban areas of China, COPD patients who were older and had more severe condition and higher number of acute exacerbations had a greater risk of high economic burden. The elderly generally have a high need for hospitalizations and caregivers partly due to increased risks of comorbidities and poor physical conditions.[@b17-copd-11-2625] Previous studies had shown the relationship between costs of COPD and acute exacerbation,[@b9-copd-11-2625],[@b22-copd-11-2625],[@b23-copd-11-2625] which was consistent with the results of this study. Acute exacerbation was a major cause of hospitalization.[@b23-copd-11-2625],[@b24-copd-11-2625] Also, exacerbations became more frequent and more severe with the severity of COPD.[@b25-copd-11-2625] And as mentioned earlier, hospitalization was identified as the largest cost category, and therefore, some measures, such as pulmonary rehabilitation, outreach nursing, multidisciplinary care, patient self-management, patient counseling and education, case management, and outreach follow-up, or services provided after discharge to decrease hospitalizations for COPD exacerbations could be helpful to cut the costs on COPD.[@b26-copd-11-2625]--[@b29-copd-11-2625]

This was a multi-center cross-sectional study conducted in urban areas of China. There were some strengths and limitations. This study was carried out in four metropolitan areas with a high response rate of 98%. The study population might well represent Chinese metropolitan population, but caution should be taken when generalizing the findings to other populations. The national economic burden estimate may be biases due to the difference in costs between rural and urban areas. As a cross-sectional study, there is a limitation for assuming causal associations between the influencing factors and costs of COPD. Another limitation was that the COPD patients of the study were not randomly selected but were selected from only four metropolitan areas of the country, which may affect the external validity. A convenient sample might be subject to selection bias although no serious ones had been identified for the study. In addition, recall biases might exist although some self-reporting information was confirmed by reviewing medical charts and searching medical records.

Conclusion
==========

COPD posed a heavy economic burden in China. Hospitalization was a major driver of the costs related to COPD. Aging, COPD severity, and acute exacerbations increased the risk of high costs for COPD.
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###### 

Demographic and clinical characteristics of COPD patients

                                                                       Male, n (%)      Female, n (%)    Total, n (%)
  -------------------------------------------------------------------- ---------------- ---------------- ----------------
  City                                                                                                   
   Beijing                                                             100 (20.2)       70 (38.0)        170 (25.1)
   Guangzhou                                                           152 (30.8)       23 (12.5)        175 (25.8)
   Shanghai                                                            125 (25.3)       43 (23.4)        168 (24.8)
   Chengdu                                                             117 (23.7)       48 (26.1)        165 (24.3)
  Age (\>60 years)                                                     417 (85.3)       140 (76.5)       557 (82.9)
  Education (years)                                                                                      
   ≤9                                                                  290 (58.7)       127 (69.4)       417 (61.6)
   10--12                                                              122 (24.7)       42 (23.0)        164 (24.2)
   \>12                                                                82 (16.6)        14 (7.7)         96 (14.2)
  Monthly household income per capita, RMB Yuan (US\$)                                                   
   \<1,000 (154)                                                       30 (6.1)         9 (4.9)          39 (5.8)
   1,000--1,999 (154--308)                                             132 (26.9)       65 (35.5)        197 (29.3)
   2,000--2,999 (309--463)                                             152 (31.0)       59 (32.2)        211 (31.4)
   3,000--3,999 (464--618)                                             74 (15.1)        20 (10.9)        94 (14.0)
   ≥4,000 (619)                                                        102 (20.8)       30 (16.4)        132 (19.6)
  Retired                                                              418 (85.1)       155 (85.6)       573 (85.3)
  Married                                                              435 (88.2)       137 (74.5)       572 (84.5)
  Current smoker                                                       119 (24.1)       12 (6.5)         131 (19.4)
  Regular exercise                                                     232 (47.5)       61 (33.5)        293 (43.7)
  Having medical insurance                                             471 (95.3)       177 (96.2)       648 (95.6)
  Course of COPD(years)[\*](#tfn1-copd-11-2625){ref-type="table-fn"}   4.0 (8.9±12.0)   4.0 (9.1±10.7)   4.0 (8.9±11.6)
  Comorbidities                                                                                          
   0                                                                   123 (24.9)       19 (10.4)        142 (21.0)
   1                                                                   172 (34.8)       61 (33.3)        233 (34.4)
   2                                                                   124 (25.1)       46 (25.1)        170 (25.1)
   ≥3                                                                  75 (15.2)        57 (31.1)        132 (19.5)
  Severity of COPD                                                                                       
   Mild                                                                88 (17.8)        52 (28.3)        140 (20.6)
   Moderate                                                            215 (43.5)       81 (44.0)        296 (43.7)
   Severe                                                              139 (28.1)       42 (22.8)        181 (26.7)
   Very severe                                                         52 (10.5)        9 (4.9)          61 (9.0)
  Total                                                                494 (72.9)       184 (27.1)       678 (100.0)

**Note:**

Data were presented as median (mean ± standard deviation).

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Annual direct and indirect costs per patient for COPD, RMB Yuan (US\$)

                                     Beijing                  Guangzhou                 Shanghai                  Chengdu                 Total
  ---------------------------------- ------------------------ ------------------------- ------------------------- ----------------------- -----------------------
  Direct costs                       7,870 (16,462±28,746)    3,773 (12,739±28,068)     6,288 (11,254±15,355)     7,071 (9,897±14,462)    6,096 (12,614±22,892)
  (1,218 \[2,549±4,451\])            (584 \[1,972±4,346\])    (974 \[1,742±2,377\])     (1,095 \[1,532±2,239\])   (944 \[1,953±3,544\])   
   Direct medical costs              6,824 (15,519±28,396)    3,178 (12,451±27,501)     5,214 (10,235±14,628)     6,628 (9,571±14,376)    5,565 (11,968±22,422)
  (1,057 \[2,403±4,396\])            (492 \[1,928±4,258\])    (807 \[1,585±2,265\])     (1,026 \[1,482±2,226\])   (862 \[1,853±3,472\])   
   Outpatient costs                  2,939 (6,480±15,748)     1,328 (2,856±3,630)       2,598 (4,670±8,339)       0 (854±3,456)           1,278 (3,730±9,481)
  (455 \[1,003±2,438\])              (206 \[442±562\])        (402 \[723±1,291\])       (0 \[132±535\])           (198 \[578±1,468\])     
   Outpatient costs per visit        434 (598±901)            190 (278±377)             212 (298±300)             0 (97±343)              156 (319±567)
  (67 \[93±139\])                    (29 \[43±58\])           (33 \[46±46\])            (0 \[15±53\])             (24 \[49±88\])          
   Hospitalization costs             0 (9,039±24,197)         0 (9,649±27,611)          0 (5,565±12,429)          6,397 (8,717±13,803)    0 (8,255±20,967)
  (0 \[1,399±3,746\])                (0 \[1,494±4,275\])      (0 \[862±1,924\])         (990 \[1,350±2,137\])     (0 \[1,278±3,246\])     
   Hospitalization costs per visit   0 (6,120±17,754)         0 (3,938±8,317)           0 (3,171±5,644)           3,695 (5,001±7,824)     0 (4,554±10,972)
  (0 \[948±2,749\])                  (0 \[610±1,288\])        (0 \[491±874\])           (572 \[774±1,211\])       (0 \[705±1,699\])       
   Direct nonmedical costs           30 (680±1,378)           0 (308±1061)              0 (848±3,691)             0 (334±1,011)           0 (539±2,092)
  (5 \[105±213\])                    (0 \[48±164\])           (0 \[131±571\])           (0 \[52±157\])            (0 \[83±324\])          
   Nutrition costs                   0 (279±561)              0 (233±781)               0 (719±3,687)             0 (142±541)             0 (341±1,914)
  (0 \[43±87\])                      (0 \[36±121\])           (0 \[111±571\])           (0 \[22±84\])             (0 \[53±296\])          
   Caregiver costs                   0 (335±984)              0 (59±458)                0 (85±306)                0 (188±856)             0 (166±718)
  (0 \[52±152\])                     (0 \[9±71\])             (0 \[13±47\])             (0 \[29±133\])            (0 \[26±111\])          
   Transportation costs              1 (67±114)               0 (16±140)                0 (44±85)                 0 (5±22)                0 (33±104)
  (0 \[10±18\])                      (0 \[2±22\])             (0 \[7±13\])              (0 \[1±3\])               (0 \[5±16\])            
  Indirect costs                     0 (5,737±12,532)         0 (558±3,135)             0 (1,456±8,436)           0 (614±3,058)           0 (2,087±8,110)
  (0 \[888±1,940\])                  (0 \[86±485\])           (0 \[225±1,306\])         (0 \[95±473\])            (0 \[323±1,256\])       
   Due to patient                    0 (2,191±6,228)          0 (52±557)                0 (882±7,958)             0 (275±2,647)           0 (843±5,240)
  (0 \[339±964\])                    (0 \[8±86\])             (0 \[137±1,232\])         (0 \[43±410\])            (0 \[131±811\])         
   Work loss, days                   0 (8.4±6.0)              0 (0.3±0.9)               0 (3.3±7.5)               0 (2.1±5.1)             0 (3.5±5.4)
  (0 \[8.4±6.0\])                    (0 \[0.3±0.9\])          (0 \[3.3±7.5\])           (0 \[2.1±5.1\])           (0 \[3.5±5.4\])         
   Due to family                     0 (3,567±9,739)          0 (506±2,998)             0 (578±2,984)             0 (339±1,591)           0 (1,247±5,522)
  (0 \[552±1,508\])                  (0 \[78±464\])           (0 \[89±462\])            (0 \[52±246\])            (0 \[193±855\])         
   Work loss, days                   0 (13.7±9.3)             0 (3.1±4.6)               0 (2.2±2.8)               0 (2.6±3.1)             0 (5.4±5.7)
  (0 \[13.7±9.3\])                   (0 \[3.1±4.6\])          (0 \[2.2±2.8\])           (0 \[2.6±3.1\])           (0 \[5.4±5.7\])         
  Total                              11,038 (22,199±35,174)   3,773 (13,277±28,759)     6,473 (12,676±17,623)     7,200 (10,510±14,934)   6,405 (14,695±25,942)
  (1,709 \[3,437±5,446\])            (584 \[2,056±4,453\])    (1,002 \[1,963±2,729\])   (1,115 \[1,627±2,312\])   (992 \[2,275±4,017\])   

**Notes:** Data were presented as median (mean ± standard deviation). Kruskal--Wallis or Wilcoxon test was used to test the differences of costs among groups.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Costs of COPD by demographic category, RMB Yuan (US\$)

                                                        Outpatient cost per visit   Hospitalization cost per visit   DMC                      DNMC                IC                        Total cost
  ----------------------------------------------------- --------------------------- -------------------------------- ------------------------ ------------------- ------------------------- ------------------------
  City                                                                                                                                                                                      
   Beijing                                              434 (598±901)               0 (6,120±17,755)                 6,824 (15,519±28,396)    30 (680±1,378)      0 (5,737±12,532)          11,038 (22,199±35,174)
  (67 \[93±139\])                                       (0 \[947±2,749\])           (1,057 \[2,403±4,396\])          (5 \[105±213\])          (0 \[888±1,940\])   (1,709 \[3,437±5,446\])   
   Guangzhou                                            190 (278±377)               0 (3,938±8,318)                  3,178 (12,451±27,501)    0 (308±1,062)       0 (558±3,135)             3,773 (13,277±28,759)
  (29 \[43±58\])                                        (0 \[610±1,288\])           (492 \[1,928±4,258\])            (0 \[48±164\])           (0 \[86±485\])      (584 \[2,056±4,453\])     
   Shanghai                                             212 (298±300)               0 (3,171±5,644)                  5,214 (10,236±14,628)    0 (848±3,691)       0 (1,456±8,436)           6,473 (12,676±17,623)
  (33 \[46±46\])                                        (0 \[491±874\])             (807 \[1,585±2,265\])            (0 \[131±571\])          (0 \[225±1,306\])   (1,002 \[1,963±2,728\])   
   Chengdu                                              0 (97±343)                  3,695 (5,001±7,824)              6,628 (9,571±14,376)     0 (334±1,011)       0 (614±3,058)             7,200 (10,510±14,934)
  (0 \[15±53\])                                         (572 \[774±1,211\])         (1,026 \[1,482±2,226\])          (0 \[52±157\])           (0 \[95±473\])      (1,115 \[1,627±2,312\])   
   *P*-value                                            \<**0.001**                 \<**0.001**                      **0.012**                \<**0.001**         \<**0.001**               \<**0.001**
  Sex                                                                                                                                                                                       
   Male                                                 156 (304±556)               0 (4,494±11,635)                 5,977 (11,963±23,020)    0 (534±2,330)       0 (1,529±6,944)           6,397 (14,123±25,051)
  (24 \[47±86\])                                        (0 \[696±1,801\])           (925 \[1,852±3,564\])            (0 \[83±361\])           (0 \[237±1,075\])   (990 \[2,187±3,879\])     
   Female                                               164 (360±596)               0 (4,715±8,980)                  4,712 (11,982±20,804)    8 (554±1,257)       0 (3,583±10,505)          6,413 (16,223±28,199)
  (25 \[56±92\])                                        (0 \[730±1,390\])           (730 \[1,855±3,221\])            (1 \[86±195\])           (0 \[555±1,627\])   (993 \[2,512±4,366\])     
   *P*-value                                            0.67                        0.704                            0.71                     **0.004**           \<**0.001**               0.726
  Age (years)                                                                                                                                                                               
   ≤60                                                  257 (351±405)               0 (1,429±3,483)                  3736 (5592±6583)         0 (121±269)         0 (3,091±11,189)          3,850 (8,804±14,253)
  (40 \[54±63\])                                        (0 \[221±539\])             (578 \[866±1,019\])              (0 \[19±42\])            (0 \[479±1,732\])   (596 \[1,363±2,207\])     
   \>60                                                 144 (314±598)               0 (5,165±11,806)                 6,096 (13,083±23,564)    0 (626±2,296)       0 (1,726±6,194)           7,071 (15,580±25,846)
  (22 \[49±93\])                                        (0 \[800±1,828\])           (944 \[2,026±3,648\])            (0 \[97±356\])           (0 \[267±959\])     (1,095 \[2,412±4,002\])   
   *P*-value                                            **0.006**                   \<**0.001**                      **0.003**                0.094               0.204                     **0.006**
  Household income per capita monthly, RMB Yuan (US≥)                                                                                                                                       
   \<1,000 (154)                                        100 (280±430)               0 (5,562±9,291)                  7,128 (13,482±19,810)    6 (357±959)         0 (3,278±9,036)           7,533 (17,368±26,818)
  (15 \[43±67\])                                        (0 \[861±1,439\])           (1,104 \[2,087±3,067\])          (1 \[55±149\])           (0 \[508±1,399\])   (1,166 \[2,689±4,152\])   
   1,000--1,999 (154--308)                              46 (241±455)                2862 (4,351±5,394)               6,993 (10,816±14,315)    0 (404±990)         0 (2,009±8,801)           7,666 (13,220±17,873)
  (7 \[37±70\])                                         (443 \[674±835\])           (1083 \[1,675±2,216\])           (0 \[63±153\])           (0 \[311±1,363\])   (1,187 \[2,047±2,767\])   
   2,000--2,999 (309--463)                              179 (363±733)               0 (4,120±7,560)                  5,429 (12,676±23,824)    0 (704±3,081)       0 (2,446±9,346)           6,825 (15,953±28,895)
  (28 \[56±114\])                                       (0 \[638±1,171\])           (841 \[1,963±3,689\])            (0 \[109±477\])          (0 \[379±1,447\])   (1,057 \[2,470±4,474\])   
   3,000--3,999 (464--618)                              198 (341±484)               0 (4,522±10,111)                 4,532 (12,038±28,767)    0 (487±1,442)       0 (2,539±7,358)           5,412 (15,173±30,497)
  (31 \[53±75\])                                        (0 \[700±1565\])            (702 \[1,864±4,454\])            (0 \[75±223\])           (0 \[393±1,139\])   (838 \[2,349±4,722\])     
   ≥4,000 (619)                                         232 (372±503)               0 (5,076±19,386)                 3,348 (11,455±23,636)    0 (594±2,053)       0 (1,041±4,493)           3,756 (13,276±25,901)
  (36 \[58±78\])                                        (0 \[786±3,001\])           (518 \[1,774±3,660\])            (0 \[92±318\])           (0 \[161±696\])     (582 \[2,056±4,010\])     
   *P*-value                                            \<**0.001**                 **0.003**                        0.54                     0.549               0.464                     0.632
  Having medical insurance                                                                                                                                                                  
   Yes                                                  157 (322±575)               0 (4,576±11,097)                 5,750 (12,112±22,706)    0 (553±2,133)       0 (2,105±8,234)           6,534 (14,889±26,309)
  (24 \[50±89\])                                        (0 \[709±1,718\])           (890 \[1,875±3,515\])            (0 \[86±330\])           (0 \[326±1,275\])   (1,012 \[2,305±4,073\])   
   No                                                   148 (263±360)               0 (4,062±7,947)                  2,954 (8758±14,656)      0 (247±754)         0 (1,688±4,857)           2,954 (10,447±15,603)
  (23 \[41±56\])                                        (0 \[629±1,230\])           (457 \[1,356±2,269\])            (0 \[38±117\])           (0 \[261±752\])     (457 \[1,618±2,416\])     
   *P*-value                                            0.535                       0.445                            0.176                    0.14                0.953                     0.183
  Current severity of COPD                                                                                                                                                                  
   Mild                                                 122 (195±281)               0 (1,908±5,401)                  2,288 (5,141±12,953)     0 (589±2,718)       0 (1,107±4,076)           2,857 (6,837±14,710)
  (19 \[30±43\])                                        (0 \[295±836\])             (354 \[796±2,006\])              (0 \[91±421\])           (0 \[171±631\])     (442 \[1,059±2,278\])     
   Moderate                                             171 (325±487)               0 (4,463±14,380)                 4,257 (10,280±19,986)    0 (525±2,329)       0 (2,629±9,055)           4,870 (13,553±26,173)
  (26 \[50±75\])                                        (0 \[691±2226\])            (659 \[1,592±3,094\])            (0 \[81±361\])           (0 \[407±1,402\])   (754 \[2,098±4,052\])     
   Severe                                               161 (339±493)               0 (5,712±7,814)                  8,408 (15,802±25,838)    10 (527±1,233)      0 (2,346±9,844)           10,350 (18,875±28,178)
  (25 \[52±76\])                                        (0 \[884±1,210\])           (1,302 \[2,447±4,000\])          (2 \[82±191\])           (0 \[363±1,524\])   (1,602 \[2,922±4,363\])   
   Very severe                                          227 (518±1215)              6,516 (7,628±7,816)              1,1316 (2,4941±31,692)   0 (531±998)         0 (1,014±2,913)           12,359 (26,377±32,059)
  (35 \[80±188\])                                       (1,009 \[1,181±1,210\])     (1,752 \[3,862±4,907\])          (0 \[82±154\])           (0 \[157±451\])     (1,913 \[4,084±4,964\])   
   *P*-value                                            **0.026**                   \<**0.001**                      \<**0.001**              **0.002**           0.75                      \<**0.001**
  Number of comorbidities                                                                                                                                                                   
   0                                                    184 (309±418)               0 (3,551±18,202)                 2,977 (7,693±19,428)     0 (548±3,577)       0 (1,311±8,768)           3,048 (9,503±22,543)
  (28 \[48±65\])                                        (0 \[550±2,818\])           (461 \[1,191±3,008\])            (0 \[85±554\])           (0 \[203±1,357\])   (472 \[1,471±3,490\])     
   1                                                    146 (205±272)               0 (3,986±6,470)                  4,874 (10,138±17,466)    0 (397±1,582)       0 (918±4,305)             5,412 (11,487±19,427)
  (23 \[32±42\])                                        (0 \[617±1,002\])           (755 \[1,570±2,704\])            (0 \[62±245\])           (0 \[142±666\])     (838 \[1,779±3,008\])     
   2                                                    106 (362±837)               0 (4,992±9,451)                  6,198 (13,513±23,177)    0 (526±1,278)       0 (1,695±4,815)           7,679 (16,014±24,356)
  (16 \[56±130\])                                       (0 \[773±1,463\])           (960 \[2,092±3,589\])            (0 \[81±198\])           (0 \[262±745\])     (1,189 \[2,479±3,771\])   
   ≥3                                                   255 (476±625)               2,765 (6,103±8,471)              9,222 (17,803±29,847)    40 (803±1,477)      0 (5,506±13,383)          13,192 (24,263±36,730)
  (39 \[74±97\])                                        (428 \[945±1,312\])         (1,428 \[2,756±4,621\])          (6 \[124±229\])          (0 \[852±2,072\])   (2,043 \[3,757±5,687\])   
   *P*-value                                            **0.002**                   \<**0.001**                      \<**0.001**              \<**0.001**         \<**0.001**               \<**0.001**

**Notes:** Data were presented as median (mean ± standard deviation). Kruskal--Wallis or Wilcoxon test was to test the differences of costs among groups. Values in bold indicated statistical significance.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; DMC, direct medical cost; DNMC, direct nonmedical cost; IC, indirect cost.

###### 

Factors related to total costs due to COPD

  Factors                                            Low burden, n                                                   High burden, n                                                  cOR (95% CI)         *P*-value     aOR (95% CI)[a](#tfn7-copd-11-2625){ref-type="table-fn"}   *P*-value[a](#tfn7-copd-11-2625){ref-type="table-fn"}
  -------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- -------------------- ------------- ---------------------------------------------------------- -------------------------------------------------------
  Sex                                                                                                                                                                                                                                                                              
   Female                                            128                                                             53                                                              1                                  1                                                          
   Male                                              370                                                             113                                                             0.74 (0.50, 1.08)    0.12          0.76 (0.46, 1.25)                                          0.284
  Age (years)                                                                                                                                                                                                                                                                      
   ≤60                                               102                                                             13                                                              1                                  1                                                          
   \>60                                              391                                                             152                                                             3.05 (1.66, 5.60)    \<**0.001**   2.36 (1.18, 4.72)                                          **0.015**
  Education (years)                                                                                                                                                                                                                                                                
   ≤9                                                290                                                             114                                                             1.94 (1.09, 3.46)    **0.025**     1.45 (0.72, 2.93)                                          0.294
   10--12                                            128                                                             36                                                              1.39 (0.72, 2.67)    0.324         1.46 (0.68, 3.15)                                          0.334
   \>12                                              79                                                              16                                                              1                                  1                                                          
  Duration of disease in years                       3.00 (8.72±11.86)[b](#tfn8-copd-11-2625){ref-type="table-fn"}   5.00 (9.74±11.12)[b](#tfn8-copd-11-2625){ref-type="table-fn"}   1.01 (0.99, 1.02)    0.334         0.99 (0.97, 1.00)                                          0.136
  Having medical insurance                                                                                                                                                                                                                                                         
   Yes                                               476                                                             159                                                             1 (0.42, 2.40)       0.996         0.60 (0.20, 1.86)                                          0.378
   No                                                21                                                              7                                                               1                                  1                                                          
  Number of comorbidities                                                                                                                                                                                                                                                          
   0                                                 122                                                             18                                                              1                                  1                                                          
   1                                                 184                                                             43                                                              1.58 (0.87, 2.87)    0.13          1.06 (0.51, 2.19)                                          0.873
   2                                                 115                                                             51                                                              3.01 (1.66, 5.45)    \<**0.001**   1.87 (0.88, 3.96)                                          0.104
   ≥3                                                76                                                              54                                                              4.82 (2.63, 8.82)    \<**0.001**   2.05 (0.93, 4.54)                                          0.076
  Monthly family per capita income, RMB Yuan (US≥)                                                                                                                                                                                                                                 
   \<1,000 (154)                                     26                                                              12                                                              1                                  1                                                          
   1,000--1,999 (154--308)                           144                                                             50                                                              0.75 (0.35, 1.60)    0.461         0.72 (0.28, 1.88)                                          0.503
   2,000--2,999 (309--463)                           154                                                             51                                                              0.72 (0.34, 1.53)    0.388         0.76 (0.29, 2.01)                                          0.586
   3,000--3,999 (464--618)                           69                                                              24                                                              0.75 (0.33, 1.72)    0.503         0.79 (0.28, 2.24)                                          0.660
   ≥4,000 (619)                                      101                                                             28                                                              0.6 (0.27, 1.34)     0.213         0.66 (0.23, 1.86)                                          0.427
  Current disease severity                                                                                                                                                                                                                                                         
   Mild                                              126                                                             12                                                              1                                  1                                                          
   Moderate                                          219                                                             64                                                              3.07 (1.60, 5.90)    **0.001**     3.26 (1.55, 6.87)                                          **0.002**
   Severe                                            110                                                             64                                                              6.11 (3.13, 11.91)   \<**0.001**   4.17 (1.91, 9.09)                                          \<**0.001**
   Very severe                                       35                                                              24                                                              7.2 (3.28, 15.83)    \<**0.001**   4.43 (1.76, 11.13)                                         **0.002**
  Exacerbations                                                                                                                                                                                                                                                                    
   No                                                437                                                             47                                                              1                                  1                                                          
   Yes                                               94                                                              68                                                              6.73 (4.36, 10.38)   \<**0.001**   4.68 (2.71, 8.08)                                          \<**0.001**
  Number of exacerbations                            1.00 (1.17±1.76)                                                2.00 (2.41±2.01)                                                1.38 (1.25, 1.52)    \<**0.001**   1.27 (1.13, 1.43)                                          \<**0.001**

**Notes:**

Adjusted for city and other variables.

Data shown as median (mean ± standard deviation). Values in bold indicated significance, *P*\<0.05.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; cOR, crude odds ratio; aOR, adjusted odds ratio.
